VB-111, is a targeted anti-cancer biologic agent that is positioned to potentially treat a wide range of solid tumors indications.
Following successful Phase 2 study, VB-111 was advanced to a Phase 3 trial in rGBM.
GLOBE was a controlled, double-arm, open-label Phase 3 study designed to evaluate our therapeutic candidate VB-111 in combination with bevacizumab (also known as Avastin) in patients with recurrent glioblastoma. Top-line results show that the study did not meet its pre-specified primary endpoint of overall survival (OS). No new safety concerns associated with VB-111 have been identified in the GLOBE study. The Company plan to conduct an in-depth analysis in order to better understand the outcome of the study and the potential activity of VB-111 in rGBM. We do not think that the results in rGBM will necessarily have implications on the prospects for VB-111 in other tumor types.